High materiality7/10
Faeth Therapeutics initiated with an Outperform at Oppenheimer
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Oppenheimer initiated Faeth Therapeutics with an Outperform rating; target 60, current price 29.24.
- Outperform initiation; target 60; price 29.24
Key facts
- 01
Target: $60
- 02
Posted price: $29.24
- 03
Analyst firm: Oppenheimer
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.